1-(2-chlorophenylamino)-propan-2-one | 503842-50-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(2-chlorophenylamino)-propan-2-one
• 英文别名: 1-[(2-Chlorophenyl)amino]acetone；1-(2-chloroanilino)propan-2-one
• CAS: 503842-50-0
• 化学式: C₉H₁₀ClNO
• 分子量: 183.637
• InChiKey: SVBBGUSPTWMRAG-UHFFFAOYSA-N

物化性质

• 沸点：
  314.6±22.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-chlorophenylamino)-propan-2-one 、 [1,1']bipiperidinyl-2,4-dione 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 生成 1-(2-chlorophenyl)-3-methyl-5-piperidin-1-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine-4-one
  参考文献：
  名称：

  Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives

  摘要：

  A series of pyrrolopyridinones was designed and synthesized as constrained analogs of the pyrazole CB-1 antagonist rimonabant. Certain examples exhibited very potent hCB-1 receptor binding affinity and functional antagonism with Ki and Kb values below 10 nM, and with high selectivity for CB-1 over CB-2 (> 100-fold). A representative analog was established to cause significant appetite suppression and reduction in body weight gain in industry-standard rat models used to develop new therapeutics for obesity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.095
• 作为产物：
  描述：

  邻氯苯胺 、 1-碘丙烷-2-酮 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以70%的产率得到1-(2-chlorophenylamino)-propan-2-one
  参考文献：
  名称：

  WO2007/39740

  摘要：

  公开号：

文献信息

• Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
  申请人：——

  公开号：US20040224970A1

  公开（公告）日：2004-11-11

  This invention relates to 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

  本发明涉及1,5,6,7-四氢吡咯并[3,2-c]吡啶衍生物，已发现其能够抑制食欲并引起减重。该发明还提供了合成该化合物的方法，包含该化合物的药物组合物，以及使用这种组合物诱导减重和治疗肥胖和肥胖相关疾病的方法。
• Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity
  申请人：Smith A. Roger

  公开号：US20060122215A1

  公开（公告）日：2006-06-08

  This invention relates to 1,5,6,7-tetrahydropynolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.

  本发明涉及1,5,6,7-四氢吡啶并[3,2-c]吡啶衍生物，发现其具有抑制食欲和诱导减重的作用。本发明还提供了合成该化合物的方法，包括该化合物的制药组合物，以及使用这样的组合物诱导减重和治疗肥胖及相关疾病的方法。
• Therapeutic agents
  申请人：Cheng Leifeng

  公开号：US20080009513A1

  公开（公告）日：2008-01-10

  The present invention relates to 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula IA and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及公式IA的4,5-二氢吡咯并[3,2-c]吡啶-4-酮化合物及其制备方法，以及它们在肥胖症、精神和神经系统疾病治疗中的应用，以及它们的治疗应用方法和包含它们的制药组合物。
• Therapeutic Agents
  申请人：Cheng Leifeng

  公开号：US20080312269A1

  公开（公告）日：2008-12-18

  The present invention relates to 4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one and 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及公式（I）的4,5,6,7-四氢吡咯并[3,2-c]吡啶-4-酮和4,5-二氢吡咯并[3,2-c]吡啶-4-酮化合物的制备方法，它们在肥胖症、精神和神经疾病的治疗中的应用，以及它们的治疗用途的方法和含有它们的制药组合物。
• PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP1432708B1

  公开（公告）日：2005-11-30